25 May 2013
Keywords: genzyme, makes, million, bid, sangstat, moves, into
Article | 11 August 2003
The USA's Genzyme is set to acquire Nasdaq-listed transplant drug specialist SangStat in a deal worth around $600 million. The
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 August 2003
4 August 2003
24 May 2013
© 2013 thepharmaletter.com